Please login to the form below

Not currently logged in
Email:
Password:

Tekmira and Pfizer research collaboration

Tekmira Pharmaceuticals and Pfizer have announced a research collaboration developing gene "silencing" RNA interference therapeutics

Tekmira Pharmaceuticals and Pfizer have announced a new research collaboration developing RNA interference (RNAi), a form of therapeutic that has the potential to treat a broad number of human diseases by "silencing" disease causing genes.

RNAi, the discovery of which was awarded the Nobel Prize for Physiology or Medicine in 2006, is a natural gene silencing mechanism used by all cells. When used as a therapeutic however, it requires a delivery technology to work effectively.

The collaboration will see Pfizer make use of Tekmira's stable nucleic acid-lipid particles (SNALP) delivery technology, a form of liquid nanoparticle, to make effective use of their own small interfering RNA (siRNA) molecules.

Tekmira will be responsible for preparing the SNALP formulations and Pfizer will evaluate the formulations in preclinical models. Financial terms of the collaboration were not disclosed.

Dr Mark J Murray, president and CEO of Tekmira, said "We are pleased to be working with Pfizer, one of the world's leading pharmaceutical companies and an organisation that has made a commitment to the development of nucleic acid therapeutics. The collaboration combines Tekmira's expertise in the delivery of RNAi therapeutics with Pfizer's research excellence in nucleic acid therapeutics."

Tekmira currently has license or collaborative agreements in place with seven other pharmaceutical and biotechnology companies, though this is their first with Pfizer.

17th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics